Mylan has entered the generic Diovan (Valsartan) fray. The company said in a statement Monday that tablets in 40mg, 80mg, 160mg and 320mg doses have launched.
The new generics increase pressure on Novartis, which had an unofficial lock on the market until June, when the FDA finally gave Ranbaxy the OK to churn out generics of the blood pressure medication from a US facility. An FDA ban on drugs produced at Ranbaxy’s plants in India kept unbranded iterations off the market because generic competitors could not market their versions until Ranbaxy had burned through its exclusive production period.
